AstraZeneca (AZN) and Daiichi Sankyo's datopotamab deruxtecan, or datroway, has received approval from the US Food and Drug Administration to treat breast cancer patients who have already undergone endocrine-based therapy and chemotherapy.
The approval is based on the results of the Tropion-Breast01 phase 3 trial, which showed a 37% reduction in the risk of disease progression or death, compared with chemotherapy, and a median progression-free survival of 6.9 months versus 4.9 months with chemotherapy, AstraZeneca said in a regulatory filing Monday.
The safety profile of datroway was in line with its known characteristics, with no new safety issues identified, the company added.
Shares of AstraZeneca were up 1.9% in recent Tuesday trading.
Price: 67.85, Change: +1.25, Percent Change: +1.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。